406 related articles for article (PubMed ID: 19131179)
1. Hypofractionated intensity-modulated radiotherapy for carcinoma of the prostate: analysis of toxicity.
Coote JH; Wylie JP; Cowan RA; Logue JP; Swindell R; Livsey JE
Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1121-7. PubMed ID: 19131179
[TBL] [Abstract][Full Text] [Related]
2. Hypofractionated accelerated radiotherapy using concomitant intensity-modulated radiotherapy boost technique for localized high-risk prostate cancer: acute toxicity results.
Lim TS; Cheung PC; Loblaw DA; Morton G; Sixel KE; Pang G; Basran P; Zhang L; Tirona R; Szumacher E; Danjoux C; Choo R; Thomas G
Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):85-92. PubMed ID: 18355982
[TBL] [Abstract][Full Text] [Related]
3. Hypofractionated intensity-modulated radiotherapy (70 gy at 2.5 Gy per fraction) for localized prostate cancer: long-term outcomes.
Kupelian PA; Thakkar VV; Khuntia D; Reddy CA; Klein EA; Mahadevan A
Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1463-8. PubMed ID: 16169683
[TBL] [Abstract][Full Text] [Related]
4. Toxicity after three-dimensional radiotherapy for prostate cancer with RTOG 9406 dose level IV.
Michalski JM; Winter K; Purdy JA; Perez CA; Ryu JK; Parliament MB; Valicenti RK; Roach M; Sandler HM; Markoe AM; Cox JD
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):735-42. PubMed ID: 14967428
[TBL] [Abstract][Full Text] [Related]
5. A dose-escalation trial with the adaptive radiotherapy process as a delivery system in localized prostate cancer: analysis of chronic toxicity.
Brabbins D; Martinez A; Yan D; Lockman D; Wallace M; Gustafson G; Chen P; Vicini F; Wong J
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):400-8. PubMed ID: 15667959
[TBL] [Abstract][Full Text] [Related]
6. Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V.
Michalski JM; Winter K; Purdy JA; Parliament M; Wong H; Perez CA; Roach M; Bosch W; Cox JD
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):706-13. PubMed ID: 15936549
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of hypofractionated image-guided intensity-modulated radiotherapy for localized prostate adenocarcinoma.
Martin JM; Rosewall T; Bayley A; Bristow R; Chung P; Crook J; Gospodarowicz M; McLean M; Ménard C; Milosevic M; Warde P; Catton C
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1084-9. PubMed ID: 17606331
[TBL] [Abstract][Full Text] [Related]
8. Role of principal component analysis in predicting toxicity in prostate cancer patients treated with hypofractionated intensity-modulated radiation therapy.
Vesprini D; Sia M; Lockwood G; Moseley D; Rosewall T; Bayley A; Bristow R; Chung P; Ménard C; Milosevic M; Warde P; Catton C
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e415-21. PubMed ID: 21477939
[TBL] [Abstract][Full Text] [Related]
9. Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer.
Fonteyne V; De Gersem W; De Neve W; Jacobs F; Lumen N; Vandecasteele K; Villeirs G; De Meerleer G
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1013-20. PubMed ID: 19386427
[TBL] [Abstract][Full Text] [Related]
10. Hypofractionated boost to the dominant tumor region with intensity modulated stereotactic radiotherapy for prostate cancer: a sequential dose escalation pilot study.
Miralbell R; Mollà M; Rouzaud M; Hidalgo A; Toscas JI; Lozano J; Sanz S; Ares C; Jorcano S; Linero D; Escudé L
Int J Radiat Oncol Biol Phys; 2010 Sep; 78(1):50-7. PubMed ID: 19910135
[TBL] [Abstract][Full Text] [Related]
11. Toxicity assessment of pelvic intensity-modulated radiotherapy with hypofractionated simultaneous integrated boost to prostate for intermediate- and high-risk prostate cancer.
McCammon R; Rusthoven KE; Kavanagh B; Newell S; Newman F; Raben D
Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):413-20. PubMed ID: 19362783
[TBL] [Abstract][Full Text] [Related]
12. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839
[TBL] [Abstract][Full Text] [Related]
13. Salvage hypofractionated radiotherapy for biochemically recurrent prostate cancer after radical prostatectomy.
Wong GW; Palazzi-Churas KL; Jarrard DF; Paolone DR; Graf AK; Hedican SP; Wegenke JD; Ritter MA
Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):449-55. PubMed ID: 17869014
[TBL] [Abstract][Full Text] [Related]
14. Intensity-modulated radiotherapy as primary therapy for prostate cancer: report on acute toxicity after dose escalation with simultaneous integrated boost to intraprostatic lesion.
Fonteyne V; Villeirs G; Speleers B; De Neve W; De Wagter C; Lumen N; De Meerleer G
Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):799-807. PubMed ID: 18407430
[TBL] [Abstract][Full Text] [Related]
15. Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes.
Cahlon O; Zelefsky MJ; Shippy A; Chan H; Fuks Z; Yamada Y; Hunt M; Greenstein S; Amols H
Int J Radiat Oncol Biol Phys; 2008 Jun; 71(2):330-7. PubMed ID: 18164858
[TBL] [Abstract][Full Text] [Related]
16. Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial.
King CR; Brooks JD; Gill H; Pawlicki T; Cotrutz C; Presti JC
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1043-8. PubMed ID: 18755555
[TBL] [Abstract][Full Text] [Related]
17. Analysis of toxicity in patients with high risk prostate cancer treated with intensity-modulated pelvic radiation therapy and simultaneous integrated dose escalation to prostate area.
Arcangeli S; Saracino B; Petrongari MG; Gomellini S; Marzi S; Landoni V; Gallucci M; Sperduti I; Arcangeli G
Radiother Oncol; 2007 Aug; 84(2):148-55. PubMed ID: 17692416
[TBL] [Abstract][Full Text] [Related]
18. High-dose intensity-modulated radiotherapy as primary therapy for prostate cancer: report on dosimetry aspects and acute toxicity in the Indian scenario.
De S; Kannan V; Deshpande S; Anand V; Ghadi Y
J Cancer Res Ther; 2010; 6(1):58-64. PubMed ID: 20479549
[TBL] [Abstract][Full Text] [Related]
19. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer.
Zelefsky MJ; Levin EJ; Hunt M; Yamada Y; Shippy AM; Jackson A; Amols HI
Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1124-9. PubMed ID: 18313526
[TBL] [Abstract][Full Text] [Related]
20. Hypofractionated radiotherapy for favorable risk prostate cancer.
Rene N; Faria S; Cury F; David M; Duclos M; Shenouda G; Souhami L
Int J Radiat Oncol Biol Phys; 2010 Jul; 77(3):805-10. PubMed ID: 20510194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
